Zhejiang Hisun Pharmaceutical Co Ltd Capital Reinvestment Ratio
Zhejiang Hisun Pharmaceutical Co Ltd capital reinvestment ratio. Zhejiang Hisun Pharmaceutical Co Ltd (600267) has a Capital Reinvestment Ratio of 0.23x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥438.43 Million) in capital expenditures (CN¥102.69 Million). Check how aggressively does Zhejiang Hisun Pharmaceutical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Zhejiang Hisun Pharmaceutical Co Ltd (1999–2025)
Capital reinvestment ratio of Zhejiang Hisun Pharmaceutical Co Ltd from 1999 to 2025. This chart tracks Zhejiang Hisun Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 27 annual periods. Also explore Zhejiang Hisun Pharmaceutical Co Ltd (600267) equity growth momentum to track the company's year-over-year net asset growth rate.
Zhejiang Hisun Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1999–2025)
Zhejiang Hisun Pharmaceutical Co Ltd capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see 600267 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | CN¥2.03 Billion | CN¥376.40 Million | ▲ +64.3% |
| 2024 | 0.11x | CN¥2.11 Billion | CN¥238.44 Million | ▼ -28.7% |
| 2023 | 0.16x | CN¥1.52 Billion | CN¥240.04 Million | ▼ -38.4% |
| 2022 | 0.26x | CN¥2.07 Billion | CN¥530.62 Million | ▼ -28.3% |
| 2021 | 0.36x | CN¥1.74 Billion | CN¥622.38 Million | ▼ -17.7% |
| 2020 | 0.44x | CN¥1.59 Billion | CN¥692.04 Million | ▼ -71.8% |
| 2019 | 1.54x | CN¥698.39 Million | CN¥1.08 Billion | ▲ +39.3% |
| 2018 | 1.11x | CN¥1.45 Billion | CN¥1.60 Billion | ▼ -6.1% |
| 2017 | 1.18x | CN¥1.24 Billion | CN¥1.46 Billion | ▼ -48.2% |
| 2016 | 2.28x | CN¥775.90 Million | CN¥1.77 Billion | ▼ -13.0% |
| 2015 | 2.62x | CN¥736.17 Million | CN¥1.93 Billion | ▼ -30.7% |
| 2014 | 3.78x | CN¥571.04 Million | CN¥2.16 Billion | ▼ -6.1% |
| 2013 | 4.02x | CN¥527.25 Million | CN¥2.12 Billion | ▼ -7.4% |
| 2012 | 4.34x | CN¥375.75 Million | CN¥1.63 Billion | ▲ +76.4% |
| 2011 | 2.46x | CN¥525.31 Million | CN¥1.29 Billion | ▲ +52.4% |
| 2010 | 1.62x | CN¥509.18 Million | CN¥823.08 Million | ▼ -11.3% |
| 2009 | 1.82x | CN¥472.85 Million | CN¥861.67 Million | ▼ -37.8% |
| 2008 | 2.93x | CN¥221.28 Million | CN¥648.25 Million | ▲ +309.2% |
| 2007 | 0.72x | CN¥437.72 Million | CN¥313.34 Million | ▼ -75.5% |
| 2006 | 2.92x | CN¥108.03 Million | CN¥315.67 Million | ▲ +23.4% |
| 2005 | 2.37x | CN¥113.53 Million | CN¥268.75 Million | ▲ +137.0% |
| 2004 | 1.00x | CN¥312.93 Million | CN¥312.52 Million | ▲ +13.5% |
| 2003 | 0.88x | CN¥288.45 Million | CN¥253.90 Million | ▼ -56.3% |
| 2002 | 2.01x | CN¥120.82 Million | CN¥243.39 Million | ▼ -47.5% |
| 2001 | 3.84x | CN¥69.14 Million | CN¥265.33 Million | ▲ +5.4% |
| 2000 | 3.64x | CN¥55.70 Million | CN¥202.76 Million | ▼ -0.3% |
| 1999 | 3.65x | CN¥32.64 Million | CN¥119.23 Million | — |